Turning new ideas into molecules that positively impact human health

News View all

Tes Pharma Receives HREC Approval to Initiate Phase I Clinical Trial of the Lead Drug TESP-0401 for Prevention of DGF Following Kidney Transplantation

Jun 12, 2026

​​​​​​​Tes Pharma Presents Results on TESP-0401 in the Adenine-Induced model of Chronic Kidney Disease at the European Renal Association (ERA) Congress 2026

Jun 3, 2026

​​​​​​​Tes Pharma Presents Results on TESP-0401 in the Adenine-Induced model of Chronic Kidney Disease at the European Renal Association (ERA) Congress 2026

Jun 3, 2026

​​​​​​​Tes Pharma Presents Results on TES-4207 at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025

Dec 10, 2025

Tes Pharma Presents Last Results on TES-AKI-01 at the 62nd European Renal Association Congress in Wien

Jun 4, 2025

Tes Pharma Presents Results on TES-ONC-07 at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 18, 2025

Professor Pellicciari awarded by President Mattarella with the Bronze Medal of Merit for Public Health

Apr 10, 2025

Tes Pharma Presents Last Results on TES-AKI-01 at the 30th Annual International Conference on Advances in Critical Care Nephrology

Feb 28, 2025

Tes Pharma Announces Appointment of Andrea Pellacani, MD, PhD, as Chief Medical Officer

Jan 29, 2025

Tes Pharma Presents Last Results on TES-AKI-01 at the 62nd European Renal Association Congress in Wien

Jun 4, 2025

Tes Pharma Announces Renewal of Research and Development Collaboration with Intercept Pharmaceuticals

Jan 14, 2025

Tes Pharma Announces Extension of its Series A Financing with Indaco Venture Partners

Dec 19, 2024

Scientific research agreement between Foro delle Arti Srl, TES Pharma Srl and Fondo XGEN Venture

Apr 10, 2024

​​​​​​​Tes Pharma Presents Results on TES-4207 at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025

Dec 10, 2025
Our Science

Combining experience with innovation across the drug discovery process
Pipeline

We are focused on delivering proprietary first-in-class drug candidates for unmet needs